Inovio Pharmaceuticals Inc Stock Research

Market Summary

USD0.96+0.01

Market Closed

1.05%

INO Stock Price

INO RSI Chart

INO Valuation

Market Cap

239.4M

Price/Earnings (Trailing)

-0.86

Price/Sales (Trailing)

23.33

EV/EBITDA

-0.71

Price/Free Cashflow

-1.1

INO Price/Sales (Trailing)

INO Profitability

EBT Margin

-2705.57%

Return on Equity

-125.84%

Return on Assets

-80.28%

Free Cashflow Yield

-90.73%

INO Fundamentals

INO Revenue

Revenue (TTM)

10.3M

Revenue Y/Y

-85.14%

Revenue Q/Q

-98.64%

INO Earnings

Earnings (TTM)

-279.8M

Earnings Y/Y

49.07%

Earnings Q/Q

-44.14%

Price Action

52 Week Range

0.954.00

(Low)(High)

Last 7 days

-15.0%

Last 30 days

-31.9%

Last 90 days

-37.2%

Trailing 12 Months

-73.7%

INO Financial Health

Current Ratio

3.25

INO Investor Care

Shares Dilution (1Y)

18.57%

Diluted EPS (TTM)

-1.17

Peers (Alternatives to Inovio Pharmaceuticals)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
BGNE	298.1B	1.4B	-4.03%	17.35%	-148.75	210.51	20.37%	-37.45%
ABBV	275.1B	58.1B	2.18%	0.81%	23.24	4.74	3.30%	2.55%
REGN	85.3B	12.2B	6.89%	19.23%	19.66	7.01	-24.26%	-46.28%
VRTX	77.6B	8.9B	3.23%	21.68%	23.36	8.69	17.91%	41.84%
ALNY	23.5B	1.0B	-5.08%	16.85%	-20.78	22.66	22.88%	-32.64%
SRPT	11.2B	933.0M	4.06%	58.34%	-15.86	11.96	32.93%	-67.99%
UTHR	9.9B	1.9B	-15.84%	20.83%	13.6	5.11	14.88%	52.86%
MID-CAP
RARE	2.6B	363.3M	-18.31%	-45.95%	-3.69	7.18	3.39%	-55.81%
MRTX	2.2B	12.4M	-14.38%	-52.88%	-3.03	180.64	-	-27.34%
SMALL-CAP
OPK	960.5M	1.0B	17.43%	-62.90%	-2.92	0.96	-43.42%	-989.45%
ANIK	408.6M	152.4M	-10.15%	6.80%	-25.95	2.68	5.37%	-174.76%
INO	239.4M	10.3M	-31.91%	-73.70%	-0.86	23.33	478.23%	7.85%
ATOS	87.4M	-	-7.38%	-53.06%	-3.6	-	-	-4.49%
TTOO	3.3M	23.8M	-29.85%	-97.83%	-0.05	0.14	-17.54%	-36.25%

Financials for Inovio Pharmaceuticals

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	-10.9%	10,262,268	11,520,729	2,658,294	2,728,738	1,774,758
Operating Expenses	-15.3%	277,835,788	328,112,421	343,446,096	321,999,134	302,992,677
S&GA Expenses	-0.1%	90,185,285	90,282,976	91,615,112	55,824,617	53,752,353
R&D Expenses	-21.1%	187,650,503	237,829,445	251,830,984	266,174,517	249,240,324
EBITDA	16.1%	-272,698,900	-324,994,644	-347,390,313	-321,119,402	-
EBITDA Margin	5.8%	-26.57	-28.21	-216	-191	-
Earnings Before Taxes	15.9%	-277,652,852	-330,137,293	-352,522,438	-326,165,085	-303,224,323
EBT Margin	5.6%	-27.06	-28.66	-219	-194	-
Interest Expenses	-11.7%	1,253,952	1,420,777	1,583,663	1,736,901	1,936,447
Net Income	15.8%	-279,818,065	-332,302,506	-354,687,651	-328,330,298	-303,658,710
Net Income Margin	5.5%	-27.27	-28.84	-221	-196	-
Free Cahsflow	0.9%	-217,184,574	-219,214,254	-198,321,425	-225,743,381	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	-11.1%	349	392	459	446	496
Current Assets	-10.0%	315	350	416	400	448
Cash Equivalents	110.7%	46.00	22.00	41.00	59.00	71.00
Net PPE	-50.4%	8.00	16.00	16.00	17.00	17.00
Goodwill	0%	11.00	11.00	11.00	11.00	11.00
Liabilities	0.7%	126	125	162	90.00	96.00
Current Liabilities	2.1%	97.00	95.00	131	59.00	66.00
Shareholder's Equity	-16.6%	222	267	298	355	400
Retained Earnings	-3.8%	-1,487	-1,433	-1,395	-1,300	-1,209
Additional Paid-In Capital	0.6%	1,711	1,701	1,694	1,642	1,610
Shares Outstanding	6.0%	249	235	219	217	-

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	0.7%	-216	-217	-196	-224	-215
Share Based Compensation	-8.9%	23.00	25.00	27.00	24.00	26.00
Cashflow From Investing	123.2%	110	49.00	60.00	121	-175
Cashflow From Financing	-33.3%	82.00	123	119	79.00	211

Risks for INO

What is the probability of a big loss on INO?

100%

Probability that Inovio Pharmaceuticals stock will be more than 20% underwater in next one year

97.3%

Probability that Inovio Pharmaceuticals stock will be more than 30% underwater in next one year.

86.9%

Probability that Inovio Pharmaceuticals stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does INO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Inovio Pharmaceuticals was unfortunately bought at previous high price.

Drawdowns

Returns for INO

Cumulative Returns on INO

-20.0%

10-Year Cumulative Returns

-26%

7-Year Cumulative Returns

-27.4%

5-Year Cumulative Returns

-47.5%

3-Year Cumulative Returns

What are the long-term rolling returns for INO?

FIve years rolling returns for Inovio Pharmaceuticals.

Annualized Returns

Which funds bought or sold INO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	reduced	-0.05	-4,727	43,273	-%
2023-03-06	Rockefeller Capital Management L.P.	unchanged	-	-	1,000	-%
2023-03-03	TIAA, FSB	unchanged	-	-2,617	22,383	-%
2023-02-28	Voya Investment Management LLC	reduced	-90.97	-1,635,660	145,345	-%
2023-02-21	MACQUARIE GROUP LTD	sold off	-100	-14,000	-	-%
2023-02-21	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	reduced	-99.63	-15,945	55.00	-%
2023-02-17	Compass Wealth Management LLC	new	-	265	265	-%
2023-02-16	American Trust	new	-	43,159	43,159	-%
2023-02-16	HARBOUR INVESTMENTS, INC.	added	60.94	482	482	-%
2023-02-15	Financial Advocates Investment Management	sold off	-100	-628,000	-	-%

Latest Funds Activity

Are funds buying INO calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own INO

No. of Funds

Inovio Pharmaceuticals News

Schedule 13G FIlings of Inovio Pharmaceuticals

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2023	state street corp	12.61%	31,472,352	SC 13G/A
Feb 09, 2023	vanguard group inc	6.83%	17,042,500	SC 13G/A
Jan 24, 2023	blackrock inc.	9.3%	23,284,119	SC 13G/A
Apr 11, 2022	state street corp	10.49%	23,267,928	SC 13G/A
Feb 11, 2022	state street corp	6.32%	13,300,430	SC 13G/A
Feb 01, 2022	blackrock inc.	8.7%	18,244,914	SC 13G/A
Feb 11, 2021	nikko asset management americas, inc.	0%	0	SC 13G/A
Feb 11, 2021	wasatch advisors inc	-	0	SC 13G/A
Feb 10, 2021	vanguard group inc	5.42%	9,185,639	SC 13G/A
Feb 10, 2021	state street corp	5.25%	8,894,555	SC 13G

INO Fair Value

Inovio Pharmaceuticals fair value in different scenarios

The table shows the Fair Value estimates for Inovio Pharmaceuticals for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	- -	- -	- -	- -	- -
Current Inflation	0.26 -72.92%	0.26 -72.92%	0.26 -72.92%	0.26 -72.92%	0.27 -71.88%
Very High Inflation	- -	- -	- -	- -	- -

Historical Inovio Pharmaceuticals Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Inovio Pharmaceuticals

View All Filings

Date Filed	Form Type	Document
Mar 13, 2023	4	Insider Trading
Mar 13, 2023	4	Insider Trading
Mar 13, 2023	4	Insider Trading
Mar 13, 2023	4	Insider Trading
Mar 01, 2023	10-K	Annual Report
Mar 01, 2023	8-K	Current Report
Mar 01, 2023	POS AM	POS AM
Mar 01, 2023	POSASR	POSASR
Feb 28, 2023	4	Insider Trading
Feb 28, 2023	4	Insider Trading

Latest Insider Trading transactions for INO

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-03-13	Weiner David B.	sold	-6,707	1.15	-5,833	-
2023-03-11	Weiner David B.	acquired	-	-	11,666	-
2023-03-11	Humeau Laurent	acquired	-	-	59,737	chief scientific officer
2023-03-11	KIES PETER	acquired	-	-	59,737	cfo
2023-03-11	KIES PETER	sold (taxes)	-35,493	1.13	-31,410	cfo
2023-03-11	Shea Jacqueline Elizabeth	sold (taxes)	-29,357	1.13	-25,980	chief executive officer
2023-03-11	Humeau Laurent	sold (taxes)	-23,343	1.13	-20,658	chief scientific officer
2023-03-11	Shea Jacqueline Elizabeth	acquired	-	-	59,737	chief executive officer
2023-02-27	Weiner David B.	sold	-14,935	1.28	-11,668	-
2023-02-26	Humeau Laurent	sold (taxes)	-35,759	1.28	-27,937	chief scientific officer

About Inovio Pharmaceuticals

Jacqueline E. Shea

www.inovio.com

320

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

INO Income Statement

2022-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues [Abstract]
Revenue from collaborative arrangements and other contracts, including affiliated entity	$ 10,262,268	$ 1,774,758	$ 7,411,220
Operating expenses:
Research and development	187,650,503	249,240,324	94,245,436
General and administrative	90,185,285	53,752,353	37,247,828
Total operating expenses	277,835,788	302,992,677	131,493,264
Loss from operations	(267,573,520)	(301,217,919)	(124,082,044)
Other income (expense):
Interest income	4,782,030	3,363,080	3,311,846
Interest expense	(1,253,952)	(1,936,447)	(8,702,450)
Change in fair value of derivative liability	0	0	(75,670,977)
(Loss) gain on investment in affiliated entities	(1,899,654)	(553,570)	36,556,658
Net unrealized (loss) gain on available-for-sale equity securities	(7,846,172)	(3,222,838)	1,695,497
Other (expense) income, net	(3,861,584)	343,371	(704,896)
Gain on deconsolidation of Geneos	0	0	4,121,075
Net loss before share in net loss of Geneos	(277,652,852)	(303,224,323)	(162,890,304)
Share in net loss of Geneos	(2,165,213)	(434,387)	(4,584,610)
Net loss	(279,818,065)	(303,658,710)	(167,474,914)
Net loss attributable to non-controlling interest	0	0	1,063,757
Net loss attributable to Inovio Pharmaceuticals, Inc.	$ (279,818,065)	$ (303,658,710)	$ (166,411,157)
Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders
Basic (in dollars per share)	$ (1.17)	$ (1.45)	$ (1.07)
Diluted (in dollars per share)	$ (1.17)	$ (1.45)	$ (1.07)
Weighted average number of common shares outstanding
Basic (in shares)	238,622,188	208,829,801	155,126,857
Diluted (in shares)	238,622,188	208,829,801	155,126,857
Convertible Bonds
Other income (expense):
Gain (loss) on extinguishment of convertible bonds and senior notes	$ 0	$ 0	$ (8,177,043)
6.50% Convertible Senior Notes Due 2024
Other income (expense):
Gain (loss) on extinguishment of convertible bonds and senior notes	$ 0	$ 0	$ 8,762,030

INO Balance Sheet

2022-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 46,329,359	$ 71,143,778
Short-term investments	206,669,397	330,170,940
Accounts receivable	1,701,726	5,466,850
Accounts receivable from affiliated entities	10,036,490	2,565,194
Prepaid expenses and other current assets	50,130,481	38,836,991
Prepaid expenses and other current assets from affiliated entities	375,227	261,192
Total current assets	315,242,680	448,444,945
Fixed assets, net	7,727,997	17,453,206
Investments in affiliated entity	2,007,142	3,906,796
Intangible assets, net	2,129,861	2,626,355
Goodwill	10,513,371	10,513,371
Operating lease right-of-use assets	10,228,207	11,571,026
Other assets	684,044	1,425,794
Total assets	348,533,302	495,941,493
Current liabilities:
Accounts payable and accrued expenses	79,686,885	47,644,530
Accounts payable and accrued expenses due to affiliated entities	1,220,439	548,032
Accrued clinical trial expenses	10,594,073	10,326,266
Deferred revenue	0	21,628
Operating lease liability	2,803,973	2,603,956
Grant funding liability	2,475,031	4,559,721
Grant funding liability from affiliated entities	87,673	37,500
Total current liabilities	96,868,074	65,741,633
Deferred revenue, net of current portion	0	64,361
Operating lease liability, net of current portion	12,655,586	15,459,559
Deferred tax liabilities	32,046	32,046
Other liabilities	0	14,826
Total liabilities	126,170,546	96,272,072
Commitments and contingencies
Inovio Pharmaceuticals, Inc. stockholders’ equity:
Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December 31, 2022 and 2021	0	0
Common stock—par value $0.001; Authorized shares: 600,000,000 at December 31, 2022 and 2021, issued and outstanding: 253,091,319 at December 31, 2022 and 217,382,887 at December 31, 2021	253,090	217,382
Additional paid-in capital	1,710,656,191	1,609,589,797
Accumulated deficit	(1,487,847,784)	(1,209,855,522)
Accumulated other comprehensive loss	(698,741)	(282,236)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity	222,362,756	399,669,421
Total liabilities and stockholders’ equity	348,533,302	495,941,493
6.50% Convertible Senior Notes Due 2024
Current liabilities:
Convertible senior notes	$ 16,614,840	$ 14,959,647